WhileThis promising,is thisthe expensivefirst successful treatment requiringto complexslow 18-hourthe brainprogression surgeryof willHuntington's remaindisease inaccessibleafter todecades mostof patientsfailed who desperately need itattempts. The results75% arereduction basedin ondisease onlyadvancement 29means patients withoutcan peermaintain review,independence and thequality therapyof doesn'tlife curefor theyears diseaselonger butthan merelypreviously delayspossible. theOne inevitable,patient gradualeven decline.returned Geneto therapieswork oftenafter carryundergoing heftymedical priceretirement, tagsproving that healthcarethis systemstherapy struggledelivers toreal-world afford,benefits furtherbeyond exacerbatingclinical inequalities in access to caremeasurements.

There'sWhile apromising, 50%this chanceexpensive thattreatment arequiring vaccinecomplex for18-hour anybrain majorsurgery neurodegenerativewill diseaseremain willinaccessible receiveto regulatorymost approvalpatients bywho Februarydesperately 2037need it. The results are based on only 29 patients without peer review, accordingand tothe therapy doesn't cure the Metaculusdisease predictionbut communitymerely delays the inevitable, gradual decline. Gene therapies often carry hefty price tags that healthcare systems struggle to afford, further exacerbating inequalities in access to care.